17 articles for BH Norman
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
12
Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.

Eli Lilly
9
Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain.

Eli Lilly
12
Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors.

Eli Lilly
11
Identification of potent and selective retinoic acid receptor gamma (RAR¿) antagonists for the treatment of osteoarthritis pain using structure based drug design.

Eli Lilly
20
Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors.

Eli Lilly
1
Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146.

Eli Lilly
7
Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency.

Monsanto
4
Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1).

Eli Lilly
21
Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1).

Eli Lilly
15
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.

Norman Drug Discovery Training and Consulting
14
Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

Lilly Research Laboratories
24
Prolyl hydroxylase inhibitors and methods of use

Akebia Therapeutics
79
Benzazepine dicarboxamide compounds

Hoffmann-La Roche
48
Drugs for treating respiratory diseases

Daiichi Sankyo
24
Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase.

University of California Irvine
40
SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.

Instituto De Quimica Medica (Csic)
28
First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.

Instituto De Quimica Medica (Csic)